Henry Schein (HSIC) is back in focus after reporting Q1 2026 results that topped analyst estimates, reaffirming 2026 guidance, and highlighting progress on value creation plans and ongoing share repurchases.

Despite better than expected Q1 results, reaffirmed 2026 guidance, and continued buybacks, Henry Schein’s short term share price performance has been weak, with a 30 day share price return of a 3.23% decline, while the 1 year total shareholder return of 8.82% shows a more constructive longer term picture and suggests recent momentum has cooled rather than broken completely.

If you like the combination of healthcare exposure and technology themes in Henry Schein’s story, it could be worth widening your search with our curated list of 32 healthcare AI stocks

With Q1 earnings ahead of expectations, reaffirmed 2026 guidance, a value score of 6, and shares trading about 20% below the average analyst target, investors may reasonably ask whether there is a genuine opportunity here or whether future growth is already priced in.

Most Popular Narrative: 19.7% Undervalued

With Henry Schein’s fair value narrative sitting at $90.21 versus a last close of $72.44, the spread between price and modeled value is hard to ignore.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion. • Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.

Curious how a modest revenue growth profile, higher margin mix, and a lower future earnings multiple combine into that fair value gap? The underlying earnings bridge, share count assumptions, and discount rate work together in a way that might surprise you.

Result: Fair Value of $90.21 (UNDERVALUED)

However, the fair value gap could close quickly if competitive pricing, staffing constraints, or execution issues on cost savings and technology projects hit margins harder than expected.

Next Steps

The mix of positives and concerns in Henry Schein’s story is clear, so this is a good moment to review the underlying numbers yourself and decide what really matters for your portfolio. To see that balance set out in one place, take a closer look at the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Henry Schein has your attention, do not stop there. Broaden your watchlist now and give yourself more options before the next opportunity passes you by.

• Spot potential underpriced opportunities early by reviewing our curated set of 44 high quality undervalued stocks that pair strong fundamentals with attractive entry points.
• Focus on income potential by scanning 12 dividend fortresses that combine higher yields with an emphasis on stability and consistent shareholder returns.
• Prioritize resilience by checking 74 resilient stocks with low risk scores designed to highlight companies with sturdier risk profiles that may better fit a cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.